Clinical Observation Of Shugan Blood Circulation Combined UDCA For Primary Biliary Cirrhosis

Background and Objectives:Primary biliary cirrhosis is a chronic, progressive cholestatic liver disease of an unknown etiology. Is more common in middle-aged women, the incidence is increasing year by year trend, and there is no special treatment. Ursodeoxycholic acid as a treatment for PBC only proven effective drugs for the treatment of PBC have a certain effect, but the UDCA unable to reduce the morbidity and mortality of the patients with PBC little effect in patients with advanced PBC. Chinese medicine through traditional diagnosis and treatment to alleviate the symptoms and signs, improve biochemical markers, immune regulation, anti-liver fibrosis, slow disease progression, and improve quality of life plays an important role. To seek new ways to improve the treatment of PBC efficacy of this subject by observing Shugan blood circulation combined ursodeoxycholic acid treatment of the clinical efficacy of the PBC, further confirmed the characteristics and advantages of Chinese medicine, in order to better solve clinical practice provide effective methods and ideas.Methods:The clinical study medical records from the Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nantong Third People’s hospital outpatient and inpatient select50cases of PBC patients met the inclusion criteria, were randomly divided into a treatment group and the control group, two groups25cases. The control group were treated to the treatment of ursodeoxycholic acid treatment, the treatment group on the basis of the control group with the Shuganlidan blood circulation side. Were observed before and after treatment in patients with PBC signs and symptoms (fatigue, skin itching, tingling flank, abdominal distension, bitter taste in the mouth, jaundice, Xiexia lump in the abdomen), Determination of biochemical parameters (serumALT, AST, ALP, GGT, TBI1, TB, APT), Determination of immunological parameters (IgA, IgG, IgM), determination of liver fibrosis markers (HA type III procollagen type IV collagen). Treatment stage0,3,6months, each detectionl. Symptom scores and laboratory tests, SPSS19.0statistical comparative analysis to determine the clinical efficacy.Results:The Shuganlidan blood circulation parties jointly UDCA can effectively improve the clinical symptoms and signs, improve liver ALT, AST, ALP, GGT, TBil, TBA, PT biochemical indicators improve liver fibrosis in patients immunological parametersaspects have significant advantages compared with the control group.Conclusion:Shuganlidan blood circulation parties jointly UDCA co-treatment of the PBC, UDCA efficacy for improving the simplex, improve PBC patients prognosis significance.